News | August 21, 2025
NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
The company’s largest center for medical device applications, serving the entire Asian market
The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
Subscribe To Our Newsletter & Stay Updated
